微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 26.28% | -10.17% | -2.84% | 122/159 | 50.16% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 27.04% | -8.71% | -6.59% | 120/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 28.95% | -1.67% | -6.63% | 114/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 31% | -3.01% | 6% | 116/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 29.25% | -3.35% | -1.25% | 119/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 29.62% | -0.92% | 0.61% | 119/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 29.44% | -3.76% | -7.9% | 113/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 31.97% | -0.05% | 5.62% | 117/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 30.26% | -4.63% | 1.22% | 117/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 29.9% | -8.77% | -2.27% | 117/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 30.59% | -8.4% | -4.35% | 115/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 31.98% | -4.19% | 0.78% | 117/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 31.73% | -3.93% | -3.17% | 114/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 32.77% | -0.4% | -1.88% | 114/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 33.4% | -0.07% | 0.06% | 111/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 33.38% | -5.85% | 1.05% | 114/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 33.03% | 0.74% | 0.4% | 107/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 32.9% | -2.72% | -1.56% | 111/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 33.42% | -7.46% | -5.73% | 104/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 35.46% | -0.88% | 8.13% | 118/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 32.79% | -5.95% | -3.05% | 103/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 33.82% | -8.01% | -6.35% | 113/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 36.12% | -2.34% | 0.97% | 94/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 35.77% | -13.19% | 2.6% | 113/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 34.86% | -15.04% | -5.18% | 99/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 36.77% | -9.66% | -0.58% | 102/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 36.98% | -11.73% | -10.24% | 84/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 41.2% | -2.33% | 0.4% | 95/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 41.04% | 6.57% | 0.83% | 73/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 40.7% | 6.03% | -2.86% | 78/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 41.9% | 17.21% | -0.69% | 71/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 42.19% | 33.08% | 9.56% | 87/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 38.51% | 40.8% | 0.32% | 75/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 38.39% | 64.62% | 7.39% | 75/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 35.74% | 72.15% | 12.75% | 75/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 31.7% | 63.76% | 15.92% | 93/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 27.35% | 41.51% | 17.29% | 81/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 23.32% | 24.28% | 12.3% | 94/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 20.76% | 18.02% | 7.26% | 82/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 19.36% | 6.41% | 0.16% | 106/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 19.33% | 14.22% | 3.01% | 78/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 18.76% | 15.6% | 6.64% | 86/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 17.59% | 3.76% | -3.29% | 76/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |